

July 2, 2026

To,
Listing Department,
National Stock Exchange Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400 051

Scrip Code – INFLUX

Dear Sir/Madam,

Sub.: Clarification with respect to the Consolidated Half-Yearly Figures in relation to the Financial Results for the Half Year and Year Ended on March 31, 2026.

In continuation of our submission dated May 20, 2026 & July 2, 2026 and with reference to the further query received from the Exchange in respect of the Financial Results submitted under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year and year ended March 31, 2026, we wish to clarify and submit as under:

Pursuant to the query raised by the Exchange and in accordance with their guidance, Company has duly modified the Consolidated Profit & Loss Statement Format in which only relevant half year figures are mentioned as the subsidiary company being Olahey Wellness Private Limited was incorporated in February 3, 2026.

The present submission is limited solely to the modification in the format of Consolidated Profit & Loss Statement of half year and year ended March 31, 2026.

In view of the above, we request your good office to kindly take this clarification along with the enclosed results on record.

Thanking you,
For Influx Healthtech Limited,

Munir Abdul Ganee Chandniwala
Managing Director
DIN: 08459582

Independent Auditor's Report on Half Year and Year ended Standalone Financial Results of Influx Healthtech Limited, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of Influx Healthtech Limited

Report on the audit of the Standalone Financial Results

We have audited the accompanying standalone financial results ('the statement') of **INFLUX HEALTHTECH LIMITED** ("the Company") for the half year and year ended March 31, 2026, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations"), including the relevant circulars issued by SEBI from time to time.

In our opinion and to the best of our information and according to the explanations given to us the aforesaid standalone financial results:

- a. are presented in accordance with the requirements of Regulations 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India, of the net profit and other financial information of the Company for the half year and year ended March 31, 2026.

Basis for opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the standalone financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our



other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial results.

Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the audited standalone annual financial statements. The Company's Board of Directors is responsible for the preparation and presentation of the statement that give a true and fair view of the net profit and other financial information in accordance with the recognition and measurement principles laid down applicable Accounting Standards prescribed under Section 133 of the Act, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this statement.



As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represent the underlying transactions and events in a manner that achieves fair presentation.



Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the financial results for the half year ended March 31, 2026 being the balancing figures between audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the half year ended September 30, 2025, which were subject to limited review.

Our opinion is not modified in respect of this matter.

Place: Mumbai
Date: 20/05/2026



FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W

Vikas Goel

(Vikas Goel)
Partner
Membership No: 039287
UDIN: 26039287ICLFTG5044

STATEMENT OF UNAUDITED/AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR AND THE YEAR ENDED MARCH 31, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

| Sr. No. | Particulars | Half Year Ended | | | For the year Ended | For the year Ended |
|---------|---|-----------------|-----------------|-----------------|--------------------|--------------------|
| | | 31.03.2026 | 30.09.2025 | 31.03.2025 | 31.03.2026 | 31.03.2025 |
| | | Unaudited | Unaudited | Unaudited | Audited | Audited |
| 1 | Income | | | | | |
| a. | Revenue from Operations | 8,006.90 | 6,676.46 | 5,679.39 | 14,683.36 | 10,485.36 |
| b. | Other Income | 124.03 | 9.46 | 10.62 | 133.49 | 13.31 |
| | Total Income | 8,130.93 | 6,685.92 | 5,690.01 | 14,816.85 | 10,498.67 |
| 2 | Expenses | | | | | |
| a. | Cost of Material Consumed | 5,012.23 | 3,909.49 | 3,368.85 | 8,921.72 | 6,340.78 |
| b. | Changes in inventories of Finished Goods | (97.06) | (155.55) | 0.89 | (252.61) | 1.16 |
| c. | Employee Benefit Expenses | 666.53 | 508.94 | 488.36 | 1,175.47 | 879.45 |
| d. | Finance Cost | 18.32 | 0.10 | 0.17 | 18.42 | 16.60 |
| e. | Depreciation & Amortization | 209.47 | 168.33 | 156.56 | 377.80 | 282.45 |
| f. | Other Expenses | 905.28 | 947.38 | 673.96 | 1,852.65 | 1,206.83 |
| | Total Expenses | 6,714.76 | 5,378.69 | 4,688.79 | 12,093.45 | 8,727.27 |
| 3 | Total Profit/(Loss) Before Exceptional Items and Tax | 1,416.17 | 1,307.24 | 1,001.22 | 2,723.40 | 1,771.40 |
| 4 | Exceptional Items | - | - | - | - | - |
| 5 | Total Profit / (Loss) Before Tax | 1,416.17 | 1,307.24 | 1,001.22 | 2,723.40 | 1,771.40 |
| 6 | Tax Expense | | | | | |
| a. | Current Tax | 365.09 | 345.38 | 245.62 | 710.47 | 440.99 |
| b. | Deferred Tax | (3.51) | (39.42) | (9.40) | (42.93) | 10.32 |
| c. | Short/ (Excess) Provision for Earlier years | - | - | - | 1.73 | (7.22) |
| 7 | Total Tax Expenses | 361.58 | 305.96 | 236.22 | 669.27 | 444.09 |
| 8 | Net Profit/(Loss) for a period (5-7) | 1,054.59 | 1,001.28 | 765.00 | 2,054.13 | 1,327.31 |
| 9 | Profit/(Loss) for The Period from discontinued operations before tax | - | - | - | - | - |
| 10 | Tax Expense of discontinued operations | - | - | - | - | - |
| 11 | Net Profit/(Loss) from discontinued operation after tax (9-10) | - | - | - | - | - |
| 12 | Net Profit/(Loss) for the year | 1,054.59 | 1,001.28 | 765.00 | 2,054.13 | 1,327.31 |
| | Paid up Equity Share Capital (Face value of Rs. 10/ each) | 2,315.04 | 2,315.04 | 1,815.00 | 2,315.04 | 1,815.00 |
| 13 | Earnings per share | | | | | |
| a. | Basic (in Rs.) | 4.56 | 4.81 | 4.21 | 9.35 | 7.31 |
| b. | Diluted (in Rs.) | 4.56 | 4.81 | 4.21 | 9.35 | 7.31 |

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M. A. Chandniwala

Munir Chandniwala
(Managing Director)

DIN : 08459582

Place: Mumbai

Date: 20/05/2026



STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON MARCH 31, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

| Particulars | As at | |
|--|------------------|-----------------|
| | 31-03-2026 | 31-03-2025 |
| | Audited | Audited |
| I EQUITY AND LIABILITIES | | |
| (1) Shareholders' fund | | |
| Share Capital | 2,315.04 | 1,815.00 |
| Reserves and Surplus | 7,760.93 | 1,799.55 |
| Total Shareholders Fund | 10,075.97 | 3,614.55 |
| (2) Non-Current Liabilities | | |
| Other Long Term Liabilities | - | 5.26 |
| Long Term Provisions | 23.43 | 17.73 |
| Total Non-Current Liabilities | 23.43 | 22.98 |
| (3) Current Liabilities | | |
| Short Term Borrowings | - | 21.92 |
| Trade Payables | 1,912.11 | 2,941.95 |
| Other Current Liabilities | 305.73 | 271.03 |
| Short Term Provisions | 53.17 | 157.48 |
| Total Current Liabilities | 2,271.01 | 3,392.38 |
| Total Equity and Liabilities | 12,370.41 | 7,029.91 |
| II ASSETS | | |
| (1) Non-Current Assets | | |
| (i) Property Plant & Equipment and Intangible Assets | | |
| Property Plant & Equipment | 2,755.22 | 1,872.50 |
| Intangible Assets | 2.83 | 3.81 |
| Capital work-in-progress | 346.91 | - |
| Intangible Assets under development | 1.69 | - |
| Total Property, Plant & Equipments | 3,106.64 | 1,876.31 |
| (ii) Non-Current Investments | 1.00 | - |
| (iii) Deferred tax assets (net) | 61.17 | 18.25 |
| (iv) Long-term loans and advances | 919.01 | 62.81 |
| (v) Other non-current assets | 137.10 | 170.57 |
| Total Non-Current Assets | 4,224.92 | 2,127.95 |
| (2) Current Assets | | |
| Current Investments | 229.99 | - |
| Inventories | 1,593.27 | 1,321.73 |
| Trade Receivables | 3,378.04 | 3,244.09 |
| Cash & Cash Equivalents | 2,515.74 | 191.06 |
| Short-term loans and advances | 393.49 | 76.56 |
| Other current assets | 34.95 | 68.52 |
| Total Current Assets | 8,145.48 | 4,901.96 |
| TOTAL ASSETS | 12,370.41 | 7,029.91 |

For and on the behalf of Board of Directors of
Influx Healthtech Limited

Munir Chandniwala

Munir Chandniwala

(Managing Director)

DIN : 08459582

Place: Mumbai

Date: 20/05/2026



STANDALONE STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

| Sl. | Particulars | For the year ended 31.03.2026 | For the year ended 31.03.2025 |
|-----------|--|----------------------------------|----------------------------------|
| | | Audited | Audited |
| A) | Cash Flow from Operating Activities | | |
| | Net Profit before tax & extraordinary items | 2,723.40 | 1,771.41 |
| | Adjustment For : | | |
| | Depreciation & Amortization Expenses | 377.80 | 282.45 |
| | Bad Debts Written Off | 36.09 | 8.49 |
| | Provision for bad and doubtful debts | 10.24 | - |
| | Reversal of Doubtful Debts (net of provision) | - | (4.00) |
| | Interest Expenses & other finance cost | 18.42 | 16.60 |
| | Interest Income | (16.66) | (5.62) |
| | Income from investments | (112.47) | - |
| | Operating Profit Before Working Capital Changes | 3,036.82 | 2,069.32 |
| | Adjusted for : | | |
| | Increase/(Decrease) in Trade payables | (1,029.85) | 1,543.92 |
| | Increase/(Decrease) in Other Current Liabilities | 26.56 | 59.69 |
| | Increase/(Decrease) in Other Non-current Liabilities | (5.26) | - |
| | Increase/(Decrease) in Provision | 5.70 | (10.94) |
| | (Increase)/Decrease in Trade Receivables | (180.27) | (1,656.99) |
| | (Increase)/Decrease in Inventories | (271.54) | (776.11) |
| | (Increase)/Decrease in Loans and Advances | (316.93) | (11.64) |
| | (Increase)/Decrease in Other Current and Non-current Assets | (41.45) | (67.45) |
| | Net Cash generated from Operating activities (before tax) | 1,223.78 | 1,149.80 |
| | (Tax Paid)/ Tax Refund - Net | (834.92) | (444.18) |
| | Net Cash Generated from Operating Activities (A) | 388.86 | 705.62 |
| B) | Cash Flow from Investing Activities | | |
| | Purchase of Property, Plant and Equipment, Capital Work in Progress, Intangible Assets and Intangible Assets under development | (2,456.19) | (821.11) |
| | Cash Outflow from Investments in securities | (118.52) | - |
| | Maturity of fixed deposit | 50.00 | (50.00) |
| | Interest Income | 7.70 | 6.64 |
| | Net Cash used in Investment Activities (B) | (2,517.01) | (864.47) |



STANDALONE STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

| Sl. | Particulars | For the year ended 31.03.2026 | For the year ended 31.03.2025 |
|-----|---|----------------------------------|----------------------------------|
| C) | Cash Flow from Financing Activities | | |
| | Proceeds from Initial Public Offer (net of issue expenses) | 4,474.75 | - |
| | Interest Expenses & other finance cost | - | (0.09) |
| | (Repayment)/ Proceeds of Short Term Borrowings | (21.92) | (10.56) |
| | Net cash generated from / (used in) Financing Activities (C) | 4,452.83 | (10.66) |
| | Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C) | 2,324.68 | (169.50) |
| | Cash and Cash Equivalents at the beginning of the Year | | |
| | Cash and cash equivalents | 191.06 | 290.56 |
| | Short term bank deposits | - | 70.00 |
| | Cash and cash equivalents at the end of the Year | 2,515.74 | 191.06 |
| | Cash and cash equivalents comprise of: | | |
| | Cash on Hand | 4.69 | 0.94 |
| | Bank Balances: | | |
| | In Current Accounts | 207.18 | 190.13 |
| | Short Term Bank Deposit | 2,303.87 | - |
| | Cash and cash equivalents at the end of the Year | 2,515.74 | 191.06 |

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M. A. Chandniwala

Munir Chandniwala
(Managing Director)

DIN : 08459582

Place: Mumbai

Date: 20/05/2026



Notes to standalone financial results for the Half Year and Year Ended 31st March, 2026

- 1 The above results have been prepared as per Generally Accepted Accounting Principles in India, prescribed u/s section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in accordance with the recognition and measurement principles laid down in Accounting Standard, as applicable, specified in Section 133 of the Companies Act, 2013 read with relevant rules framed thereunder or as specified by the Institute of Chartered Accountants of India, whichever is applicable.
- 2 The above results for the half year and year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 20th, 2026.
- 3 The results for the half year and year ended March 31, 2026 has been audited by the Statutory Auditors of the Company, M/s V. B. Goel & Co. Chartered Accountants as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
- 4 Since there are no separate reportable business segments, the disclosure requirements as per AS 17 "Segment Reporting" are not applicable.
- 5 The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share in accordance with the Accounting Standard 20.
- 6 The basic and diluted EPS for the half year ended Mar 31 2026, Sep 30 2025 and Mar 31 2025 are not annualised.
- 7 Previous period figures have been re-grouped and re-classified wherever necessary.
- 8 The statement includes the results for the half year ended March 31, 2026 being the balanced figure between audited figures in respect of the full financial year and the published un-audited figures in respect of 1st half year of the current financial year, which were subject to limited review by the statutory auditors.
- 9 There were no investor complaints known to the Company outstanding at the beginning and at the year ended
- 10 As the Company is listed on SME Emerge platform of National Stock Exchange of India Limited, the requirement of submitting "year to date" financial result is not applicable under Regulation 33(5) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

mb.



- 11 The standalone financial results pertaining to the half year ended March 31, 2025 have not been subject to limited review or audit and have been presented based on the information compiled by the Management. The Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs in accordance with the Accounting Standards (AS).
- 12 The results of the Company are also available for investors at www.influxhealthtech.com
- 13 The company has completed fresh issue of Equity Shares by Initial Public Offer ("IPO") of 50,00,400 Equity Shares of face value Rs.10 each at an issue price of Rs. 96 per equity share. The Equity Shares of the company were listed on National Stock Exchange of India Limited ("NSE") Emerge Platform on June 25, 2025. The details of utilization of the net proceeds as mentioned below:

| Sr No. | Objects as disclosed in the offer document | Amount disclosed in offer document | Amount utilized upto 31.03.2026 | Unutilized amount as on 31.03.2026 |
|--------|---|------------------------------------|---------------------------------|------------------------------------|
| 1 | Funding Capital expenditure requirements for setting up of manufacturing facilities | 3,673.34 | 1,384.15 | 2,289.19 |
| 2 | General Corporate Purpose | 667.40 | 667.40 | - |
| 3 | Public Issue Expenses | 583.24 | 583.24 | - |
| | Total | 4,923.98 | 2,634.79 | 2,289.19 |

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M. A. Chandniwala
Munir Chandniwala
(Managing Director)
DIN : 08459582
Place: Mumbai
Date: 20/05/2026



Independent Auditor's Report on Audited Annual Consolidated Financial Results of Influx Healthtech Limited, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of Influx Healthtech Limited

Report on the audit of the Consolidated Financial Results

We have audited the accompanying consolidated financial results ('the statement') of **INFLUX HEALTHTECH LIMITED** (hereinafter referred to as the 'Holding Company') and its subsidiary (Holding Company and its subsidiaries together referred to as 'the Group') for the year ended March 31, 2026, attached herewith being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial results:

- a. include the annual financial results of the following entity :
 1. Influx Healthtech Limited
 2. Olahey Wellness Private Limited
- b. are presented in accordance with the requirements of Regulations 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India, of the net profit and other financial information of the Company for the half year and year ended March 31, 2026.



Basis for opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Companies Act, 2013 ('the Act'). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the consolidated financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the consolidated financial results.

Management's Responsibilities for the Consolidated Financial Results

These Consolidated financial results have been compiled from the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the consolidated net profit and other financial information of the Group in accordance with the recognition and measurement principles laid down applicable Accounting Standards prescribed under Section 133 of the Act, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been



used for the purpose of preparation of the consolidated financial results by the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of their respective companies, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of their respective companies..

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Group have adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/information of the entities within the Group to express an opinion on the consolidated financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors.



Materiality is the magnitude of misstatements in the consolidated financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated annual financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial Results.

We communicate with those charged with governance of the Holding Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Place: Mumbai
Date: 20/05/2026



FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W

VS

(Vikas Goel)
Partner
Membership No: 039287
UDIN: 26039287XRHKKR4380

INFLUX HEALTHTECH LIMITED

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR AND YEAR ENDED MARCH 31, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

| Sr. No. | Particulars | Half Year Ended | For the year Ended |
|---------|--|-----------------|--------------------|
| | | 31.03.2026 | 31.03.2026 |
| | | Unaudited | Audited |
| 1 | Income | | |
| a. | Revenue from Operations | | |
| b. | Other Income | 8,006.90 | 14,683.36 |
| | Total Income | 124.03 | 133.49 |
| 2 | Expenses | | |
| a. | Cost of Material Consumed | 5,012.23 | 8,921.72 |
| b. | Changes in inventories of Finished Goods | (97.06) | (252.61) |
| c. | Employee Benefit Expenses | 666.53 | 1,175.47 |
| d. | Finance Cost | 18.32 | 18.42 |
| e. | Depreciation & Amortization | 209.47 | 377.80 |
| f. | Other Expenses | 905.62 | 1,853.00 |
| | Total Expenses | 6,715.11 | 12,093.80 |
| 3 | Total Profit/(Loss) Before Exceptional Items and Tax | 1,415.82 | 2,723.05 |
| 4 | Exceptional Items | - | - |
| 5 | Total Profit / (Loss) Before Tax | 1,415.82 | 2,723.05 |
| 6 | Tax Expense | | |
| a. | Current Tax | 365.09 | 710.47 |
| b. | Deferred Tax | (3.59) | (43.02) |
| c. | Short/(Excess) Provision for Earlier years | - | 1.73 |
| 7 | Total Tax Expenses | 361.49 | 669.18 |
| 8 | Net Profit/(Loss) for a period (5-7) | 1,054.33 | 2,053.87 |
| 9 | Profit/(Loss) for The Period from discontinued operations before tax | - | - |
| 10 | Tax Expense of discontinued operations | - | - |
| 11 | Net Profit/(Loss) from discontinued operation after tax | - | - |
| 12 | Net Profit/(Loss) for the year | 1,054.33 | 2,053.87 |
| | Paid up Equity Share Capital (Face value of Rs. 10/- each) | 2,315.04 | 2,315.04 |
| 13 | Earnings per share | | |
| a. | Basic (in Rs.) | 4.55 | 9.35 |
| b. | Diluted (in Rs.) | 4.55 | 9.35 |

For and on the behalf of Board of Directors of
Influx Healthtech Limited

Munir Chandniwala

Munir Chandniwala
(Managing Director)
DIN : 08459582

Place: Mumbai
Date: 20/05/26

INFLUX HEALTHTECH LIMITED

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS ON MARCH 31, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

| Particulars | As at | |
|--|------------------|----------------|
| | 31-03-2026 | 31-03-2025 |
| | Audited | (Refer Note 9) |
| I EQUITY AND LIABILITIES | | |
| (1) Shareholders' fund | | |
| Share Capital | 2,315.04 | NA |
| Reserves and Surplus | 7,760.67 | NA |
| Total Shareholders Fund | 10,075.71 | NA |
| (2) Non-Current Liabilities | | |
| Long Term Provisions | 23.43 | NA |
| Total Non-Current Liabilities | 23.43 | NA |
| (3) Current Liabilities | | |
| Trade Payables | 1,912.26 | NA |
| Other Current Liabilities | 305.73 | NA |
| Short Term Provisions | 53.17 | NA |
| Total Current Liabilities | 2,271.16 | NA |
| Total Equity and Liabilities | 12,370.30 | NA |
| II ASSETS | | |
| (1) Non-Current Assets | | |
| (i) Property Plant & Equipment and Intangible Assets | | |
| Property Plant & Equipment | 2,755.22 | NA |
| Intangible Assets | 2.83 | NA |
| Capital work-in-progress | 346.91 | NA |
| Intangible Assets under development | 1.69 | NA |
| Total Property, Plant & Equipments | 3,106.65 | NA |
| (ii) Deferred tax assets (net) | 61.26 | NA |
| (iii) Long-term loans and advances | 919.01 | NA |
| (iv) Other non-current assets | 137.10 | NA |
| Total Non-Current Assets | 4,224.03 | NA |
| (2) Current Assets | | |
| Current Investments | 229.99 | NA |
| Inventories | 1,593.27 | NA |
| Trade Receivables | 3,378.04 | NA |
| Cash & Cash Equivalents | 2,516.54 | NA |
| Short-term loans and advances | 393.49 | NA |
| Other current assets | 34.95 | NA |
| Total Current Assets | 8,146.28 | NA |
| TOTAL ASSETS | 12,370.30 | NA |

For and on the behalf of Board of Directors of
Influx Healthtech Limited

Munir Chandniwala
Munir Chandniwala
(Managing Director)
DIN : 08459582

Place: Mumbai

Date: 20/05/2026

INFLUX HEALTHTECH LIMITED

CONSOLIDATED STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

| Sl. | Particulars | For the year ended | For the year ended |
|-----------|--|--------------------|--------------------|
| | | 31.03.2026 | 31.03.2025 |
| | | Audited | (Refer Note 9) |
| A) | <u>Cash Flow from Operating Activities</u> | | |
| | Net Profit before tax & extraordinary items | 2,723.05 | NA |
| | <u>Adjustment For :</u> | | |
| | Depreciation & Amortization Expenses | 377.80 | NA |
| | Bad Debts Written Off | 36.09 | NA |
| | Provision for bad and doubtful debts | 10.24 | NA |
| | Interest Expenses & other finance cost | 18.42 | NA |
| | Interest Income | (16.66) | NA |
| | Income from investments | (112.47) | NA |
| | Operating Profit Before Working Capital Changes | 3,036.47 | NA |
| | Adjusted for : | | |
| | Increase/(Decrease) in Trade payables | (1,029.70) | NA |
| | Increase/(Decrease) in Other Current Liabilities | 26.56 | NA |
| | Increase/(Decrease) in Other Non-current Liabilities | (5.26) | NA |
| | Increase/(Decrease) in Provision | 5.70 | NA |
| | (Increase)/Decrease in Trade Receivables | (180.28) | NA |
| | (Increase)/Decrease in Inventories | (271.54) | NA |
| | (Increase)/Decrease in Loans and Advances | (316.93) | NA |
| | (Increase)/Decrease in Other Current and Non-current Assets | (41.45) | NA |
| | Net Cash generated from Operating activities (before tax) | 1,223.57 | NA |
| | (Tax Paid)/ Tax Refund - Net | (834.92) | NA |
| | Net Cash Generated from Operating Activities (A) | 388.65 | NA |
| B) | <u>Cash Flow from Investing Activities</u> | | |
| | Purchase of Property, Plant and Equipment, Capital Work in Progress, Intangible Assets and Intangible Assets under development | (2,456.19) | NA |
| | Investment in Securities | (117.52) | NA |
| | Maturity of fixed deposit | 50.00 | NA |
| | Interest Income | 7.70 | NA |
| | Net Cash used in Investment Activities (B) | (2,516.01) | NA |

mb

INFLUX HEALTHTECH LIMITED

CONSOLIDATED STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

| Sl. | Particulars | For the year ended 31.03.2026 | For the year ended 31.03.2025 |
|-----|---|----------------------------------|----------------------------------|
| C) | Cash Flow from Financing Activities | | |
| | Proceeds from Initial Public Offer (net of issue expenses) | 4,474.75 | NA |
| | (Repayment)/ Proceeds of Short Term Borrowings | (21.92) | NA |
| | Net cash generated from / (used in) Financing Activities (C) | 4,452.83 | NA |
| | Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C) | 2,325.47 | NA |
| | Cash and Cash Equivalents at the beginning of the Year | | |
| | Cash and cash equivalents | 191.06 | NA |
| | Short term bank deposits | - | NA |
| | Cash and cash equivalents at the end of the Year | 2,516.54 | NA |
| | Cash and cash equivalents comprise of: | | |
| | Cash on Hand | 4.69 | NA |
| | Bank Balances: | | |
| | In Current Accounts | 207.98 | NA |
| | Short Term Bank Deposit | 2,303.87 | NA |
| | Cash and cash equivalents at the end of the Year | 2,516.54 | NA |

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M. A. Chandniwala

Munir Chandniwala
(Managing Director)

DIN : 08459582

Place: Mumbai

Date: 20/05/2026

INFLUX HEALTHTECH LIMITED

Notes to consolidated financial results for the Year Ended March 31, 2026

- 1 The consolidated financial results of Parent and its subsidiaries [collectively referred as 'Group'], include the result of the Company and following entities:

| Company Name | Consolidated as |
|---------------------------------|-----------------|
| Olahey Wellness Private Limited | Subsidiary |

- 2 The above results have been prepared as per Generally Accepted Accounting Principles in India, prescribed u/s section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in accordance with the recognition and measurement principles laid down in Accounting Standard, as applicable, specified in Section 133 of the Companies Act, 2013 read with relevant rules framed thereunder or as specified by the Institute of Chartered Accountants of India, whichever is applicable.
- 3 The above results for the year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on May 20th, 2026
- 4 The results for the year ended March 31, 2026 has been audited by the Statutory Auditors of the Company, M/s V. B. Goel & Co. Chartered Accountants as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
- 5 Since there are no separate reportable business segments, the disclosure requirements as per AS 17 "Segment Reporting" are not applicable.
- 6 The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share in accordance with the Accounting Standard 20.
- 7 The results of the Company are also available for investors at www.influxhealthtech.com.
- 8 Comparative figures for the previous year have not been presented since the consolidated financial statements are prepared for the first time in accordance with the transition provision stated in paragraph 30 of Accounting Standard 21 "Consolidated Financial Statements".
- 9 This consolidated results are the First Consolidated Financial Results of the Company since the Holding Company acquired its first subsidiary in February 2026. Since the subsidiary did not exist as on and for the half year ended September 30, 2025, no half-yearly consolidated figures exist for the said period.

MB

- 10 The Holding company has completed fresh issue of Equity Shares by Initial Public Offer ("IPO") of 50,00,400 Equity Shares of face value Rs.10 each at an issue price of Rs. 96 per equity share. The Equity Shares of the company were listed on National Stock Exchange of India Limited ("NSE") Emerge Platform on June 25, 2025. The details of utilization of the net proceeds as mentioned below:

| Sr No. | Objects as disclosed in the offer document | Amount disclosed in offer document | Amount utilized upto 31.03.2026 | Unutilized amount as on 31.03.2026 |
|--------|---|------------------------------------|---------------------------------|------------------------------------|
| 1 | Funding Capital expenditure requirements for setting up of manufacturing facilities | 3,673.34 | 1,384.15 | 2,289.19 |
| 2 | General Corporate Purpose | 667.40 | 667.40 | - |
| 3 | Public Issue Expenses | 583.24 | 583.24 | - |
| | Total | 4,923.98 | 2,634.79 | 2,289.19 |

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M. A. Chandniwala

Munir Chandniwala
(Managing Director)
DIN : 08459582

Place: Mumbai

Date: 20/05/26

To,
The Board of Directors
Influx Healthtech Limited

We, the statutory auditors of Influx Healthtech Limited having registered office at 109, Ghanshyam Enclave Premises Co-op Soc, Plot No. 856, Laljipada, Kandivali West, Mumbai - 400067 have verified the books of accounts of the Company and other relevant records produced before us. On the basis of such verification and according to information and explanations given to us, we confirm that the company has utilized the following amount from the issue proceeds.

(Rupees in Lakhs)

| Sr. No. | Objects as disclosed in the Offer document | Amount disclosed in the Offer document | Actual Utilized Amount upto 31.03.2026 | Unutilized Amount as on 31.03.2026 |
|--------------|--|--|--|------------------------------------|
| 1 | Funding Capital expenditure requirements for setting up of manufacturing facilities for Nutraceutical Division | 2,249.11 | 1,176.18 | 1,072.93 |
| 2 | Funding Capital expenditure requirements for setting up of manufacturing facilities for Veterinary Food Division | 1,148.58 | 138.00 | 1,010.58 |
| 3 | Purchase of Machineries for Homecare and Cosmetic Division | 275.65 | 69.97 | 205.68 |
| 4 | General Corporate Purpose | 667.40 | 667.40 | - |
| 5 | Public Issue Expenses | 583.24 | 583.24 | - |
| Total | | 4,923.98 | 2,634.79 | 2,289.19 |

This Certificate is intended for your information or to be provided to any entity or Regulatory Authority in connection with the utilization of issue proceeds and is not to be used, referred to or distributed for any other purpose without our written consent.

FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W



WS

(Vikas Goel)
Partner
Membership No: 039287
UDIN: 26039287OMLEFV5109

Place: Mumbai
Date: 20/05/2026